The Nantucket Hotel & Resort
77 Easton Street
Nantucket, Massachusetts
Contact
If you have any questions please contact Laura Melanson at nantucketretina@gmail.com.
This is a past event. Registration is closed. View other Nantucket Retina Society events.
Jul'2022
27 - 29 (EDT)
Nantucket
Since its first meeting in 1986, Nantucket Retina has provided an informal forum for active, open, and innovative discussions between junior members of the retina community and senior retina specialists, joined by a select group of talented representatives from companies with vitreoretinal expertise.
A Message from the Meeting Organizers
We are thrilled to reconvene on beautiful Nantucket in Summer 2022 for the 36th annual meeting of Nantucket Retina. We hope you'll join us July 27-29, 2022 at The Nantucket Hotel + Resort! For those unfamiliar with The Nantucket Hotel, it is an incredible venue with luxury accommodations, the island's best meeting space, award-winning hospitality, and tons of kid-friendly amenities--all conveniently located in the heart of downtown Nantucket. This will be our first time hosting the meeting at The Nantucket Hotel and we couldn't be more excited for what's sure to be the start of a great tradition.
In our continuing efforts to ensure the most engaging and lively exchange of ideas, the format of the meeting will provide for physician and fellow participants to present a 15-minute talk on an interesting aspect of retinal diseases. The focus may be original scientific work, a case report, experience with a new surgical technique or instrument, or even a straightforward thematic question of interest. As is tradition, the organizing committee will work together in the weeks leading up to the meeting to review and organize registrants' abstract and title submissions and will structure the program to provide plenty of time for lively discussion around each topic. Please feel free to contact us (NantucketRetina@gmail.com) if you would like to have our thoughts about a topic you might present. Corporate participants are also encouraged to speak during the meeting: each company is allotted a 10-minute window to present on a topic of its choosing. In order to keep this meeting small and informal, participation is limited to 60 registrants.
See you in July,
Charles C. Barr, MD
Don D'Amico, MD
Szilard Kiss, MD
Mike Lambert, MD
Craig Sklar, MD
HighlightsHighlights
3Days
102Attendees
6Sessions
VenueVenue
SponsorsSponsors
Organizer
2022 Premier Sponsors
2022 Participating Corporate Partners
Nantucket Retina Society
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 23,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
EyePoint Pharmaceuticals
About EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.
Mallinckrodt Pharmaceuticals
Mallinckrodt is a global business that develops, manufactures, markets and distributes biopharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Samsara Vision
Samsara Vision is a privately held specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. We believe that rejuvenating eyesight revives the spirit, allowing people to reconnect to the things in life that they love to see and do. Our approach includes working collaboratively with health care providers, researchers, payers, and advocates to ensure that people living with deteriorating vision have access to our novel technologies and support paths thereby better ensuring a future where they can see anew. Learn more at https://www.samsaravision.com/
Spark Therapeutics
At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. We currently have four programs in clinical trials. At Spark, a member of the Roche Group, we see the path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn.
American Society of Cataract and Refractive Surgery
Since its founding in 1974, the American Society of Cataract and Refractive Surgery (ASCRS) has been at the forefront of anterior segment surgery and has established itself as a trusted resource for cataract, refractive, cornea, and glaucoma surgeons. For more than 40 years, ASCRS has been committed to advancing the art and science of ophthalmic surgery as a primary source for the latest clinical information, published research, and regulatory updates affecting anterior segment surgeons and the patients they serve. ASCRS’ innovation is focused on three critical areas: Education, Philanthropy, and Advocacy. We provide our members with robust clinical and practice management education and work with patients, government, and the medical community to promote the delivery and advancement of high-quality eyecare.
Genentech
Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA) and other retinal diseases. Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
Regeneron
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases. For more information, please visit www.Regeneron.com or follow @Regeneron on Twitter.
SparingVision
SparingVision is a genomic medicines company, translating pioneering science into vision saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is SPVN06, a gene independent treatment for retinitis pigmentosa (RP), the most common inherited retinal disease affecting two million people worldwide. SPVN06 could form the basis of a suite of new sight saving treatments as it could be applicable to many other retinal diseases, regardless of genetic cause. The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.
CommunityCommunity
Connect with 94 people attending this event
EDCS